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Abstract
Inherited Multicentric Osteolysis (IMO) is an uncommon familial condition of idiopathic pathophysiology causing
bone osteolysis and dysplasia. These patients present with common rheumatologic complaints of pain, dysfunction
and disability, and are often initially misdiagnosed as a chronic rheumatic disease of childhood such as juvenile
idiopathic arthritis. We report a case of three siblings diagnosed with IMO. Diagnosis was made during childhood,
with each sibling having different manifestations and course of disease. One had a previous history of bilateral hip
dysplasia. Two had osteolysis of the foot, distal tibia and femur (lower limb bones), whilst one had osteolysis of the
rib and unusual clavicular fractures. Unusually, all siblings appear to experience decreased pain sensation compared
to norms. All siblings were treated with bisphosphonates and experienced a rapid improvement in pain symptoms,
decreased analgesic requirements. Two had bone mineral density testing performed and both had increases post-
bisphosphonate. In all three, there was subjective evidence of stabilisation of bone disease. Testing for matrix
metalloproteinase-2 (MMP2) gene was negative.
Introduction
Inherited multicentric osteolysis (IMO) is a rare familial
skeletal condition characterised by osteolysis leading to
bone dysplasia. Patients subsequently experience pain,
dysfunction and disability. First described in 1838 by
Jackson [1], IMO has been infrequently reported in
international literature with synonymous names such as
‘vanishing bone’ syndrome, inherited osteolysis/arthritis
syndromes, multicentric carpal-tarsal osteolysis, nodulo-
sis arthropathy and osteolysis (NAO) syndrome, and
Torg-Winchester syndrome [1-3]. The heterogeneity of
independent case reports of syndromes sharing similar
manifestations and radiologic findings of osteolysis led
to grouping by the International Skeletal Dysplasia
Society into an “osteolysis” group (Table 1) [4].
The disorders grouped in this fashion still had some
distinct differences in clinical features, associations, and
anatomic locations. Similarities exist between these dis-
orders in that they were familial, and that the primary
pathophysiology was of abnormal osteolytic bone caus-
ing pain, dysfunction, and disability. In some cases, IMO
has other additional clinical manifestations including
facial dysmorphism, nephropathy, and neurologic
dysfunction. None have been associated with bilateral
hip dysplasia.
IMO is often initially misdiagnosed as it mimics other
chronic rheumatic disorders such as juvenile idiopathic
arthritis [5]. A genetic aetiology is likely, however with the
precise genetic mechanisms not yet understood. Studies
have shown links of some form of IMO with mutation in
gene 16q12-21 which encodes matrix metalloproteinase-2
gene (MMP2). MMP2 deficiency or lack of activity is
hypothesised to cause extracellular matrix breakdown,
leading to disturbance in bony remodelling favouring
osteolysis [1].
Bisphosphonate therapy was commenced in all three
children. Bisphosphonates are agents which decrease
osteoclastic activity, hence favouring bone formation [6].
Extensive literature supports bisphosphonate use in
adults [7,8]. Bisphosphonates are now used in the pae-
diatric population to successfully treat a variety of con-
ditions including osteoporosis and osteogenesis
imperfecta. Paediatric case reports suggest that bispho-
sphonates may have analgesic effects, improve range of
movement and function, improve BMD, and potentially
improve the natural history of osteonecrosis [9-12].
Some of these studies have shown reduced risk of frac-
tures, but overall data to date is inconclusive. Similarly,* Correspondence: senq.lee@health.wa.gov.au;
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data on risk of further surgical intervention is
inconclusive.
We present a report of three siblings of a non-consan-
guineous Caucasian family diagnosed with a possibly
unique form of IMO treated with bisphosphonates, seen
in our Rheumatology Department of a tertiary paediatric
hospital. Consent and permission to publish relevant
information, clinical photos, and radiologic images were
obtained from the parents of the three siblings.
Clinical reports
Case 1
Sibling A is the eldest female sibling of a family
who migrated from New Zealand to Australia. Currently
12 years old, she was first seen by our Rheumatology team
at age 9 when referral was made from Orthopaedics for
management of worsening lower leg disease.
Sibling A was initially seen by an Orthopaedic surgeon
during infancy and diagnosed with bilateral developmen-
tal dysplasia of the hips, surgically repaired at 17 months
of age. At 2 years of age, she presented with a painless
deformity of her left ankle. At this stage she was still
physically active, participating in ballet. Imaging (X-ray
and MRI) revealed osteonecrosis of the left talar body,
os calcis, and cuboid. Initial management was with
analgesia, rest, casting and splinting with an ankle foot
orthosis. Her condition gradually deteriorated over time.
At age 4 she developed idiopathic osteonecrosis of her
left third metatarsal. Biopsies of the osteonecrotic sites
confirmed osteonecrosis with negative bacterial cultures.
At age 6 she suffered an atraumatic painless fracture of
her right first metacarpal.
Her younger sister started developing similar problems
at this stage and both were referred to a Geneticist and
Neurologist for assessment and diagnostic assistance.
Differential diagnoses included a familial osteolytic
disorder, or possible congenital insensitivity to pain syn-
drome. Sibling A’s disease progressed, involving her
right talus at age 7. At this stage she had bilateral lower
limb disease [Figure 1, 2].
Clinical examination on first review by a rheumatolo-
gist at age 9 revealed a well child with bilateral gross
deformities of her ankles and feet [Figure 3]. There was
no dysmorphic features. She had scars on her hips from
previous surgical repair of bilateral hip dysplasia. Height
and weight were progressing normally for age during
early childhood. Developmental examination was normal
for age. Neurological examination showed a mild subjec-
tive decrease in pain sensation generally, but was other-
wise normal. Serologic testing revealed a mild elevation
of ESR (20 mm/hr) but FBP U&E ANA CRP were nor-
mal. At this stage no biopsies or cultures were per-
formed. Metabolic studies were normal, and nerve
conduction velocities revealed intact motor function but
borderline delayed sensory function. Testing for muta-
tion of MMP2 gene was negative.
Initial discussions led to a favoured diagnosis of her-
editary sensory and autonomic neuropathy (HSAN),
however we felt that a more accurate diagnosis was
IMO given her disease presentation and clinical progres-
sion, later assisted by investigation findings of multiple
aseptic osteolytic lesions. The mode of inheritance was
thought to be autosomal recessive as generations of the
family were not affected. Treatment was initiated with
regular non-steroidal anti-inflammatory medication
(NSAID) with good analgesic effect.
Six months later she developed a Staphylococcus Aur-
eus septic arthritis of her right ankle, and was treated
with IV Benzylpenicillin and oral Rifampicin. At age 10
she was diagnosed with an atraumatic impaction or col-
lapse of her distal left femur, with multiple areas of
osteolysis surrounding the fracture [Figure 4].
Table 1 New Nomenclature from Nosology and Classification of Genetic Skeletal Disorders (2006 Revision) Osteolysis
group - adapted from International Skeletal Dysplasia Society with permission [4].
Name of disorder Inheritance MIM Locus Gene Protein MIM Notes
Familial expansile osteolysis AD 174810 18q22.1 TNFRSF11A RANK 603499
Infantile systemic hyalinosis AR 236490 4q21 CMG2 Capillary
morphogenesis
gene 2
608041 Incl. Juvenile hyaline fibromatosis
(JHF, 228600) and Puretic syndrome
Mandibuloacral dysplasia type A AR 248370 1q21.2 LMNA Lamin A/C 150330
Progeria, Hutchinson-Gilford type AD 176670 1q21.2 LMNA Lamin A/C 150330
Mandibuloacral dysplasia type B AR 608612 1p34 ZMPSTE24 Zinc
metalloproteinase
606480







Hadju-Cheney syndrome AD 102500
Multicentric carpal-tarsal osteolysis
with and without nephropathy
AD 166300
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Complications followed - firstly non-union of her frac-
ture, treated conservatively with immobilisation and non
weight bearing. She then developed S. Aureus osteomye-
litis of her left knee lesion, again treated successfully
with a course of IV Flucloxacillin and oral Rifampicin.
ESR and CRP were significantly elevated during periods
of infection. ESR remained persistently mildly elevated
(20 to 30 mm/hr) during the course of disease.
Bisphosphonate therapy for IMO was commenced as
there were concerns about the non-union of her left dis-
tal femoral fracture, gradually worsening osteolysis, and
potential complete fragmentation of the distal femoral
condyles. She was treated at age 10 1/2 years old with
intravenous Pamidronate at an initial dose of 0.5 mg/kg,
increasing to 1 mg/kg for following doses. Treatment
was performed monthly for six months. Oral calcium
and Vitamin D supplements were also commenced.
Bisphosphonates provided some apparent benefits
including an acute improvement in pain, however there
was no difference in range of motion and function.
Impact on disease progression was difficult to assess.
Following bisphosphonate therapy, there was no
improvement in existing osteolytic disease, but there
was gradual healing and union of her left distal femoral
fracture over time. To date she has not had any new
fractures, and no new focal areas of osteolysis. Bone
mineral density improved, with whole body BMD
improving from 0.66 (z score -2.56) to 0.96 (z -0.1) after
12 months. Similarly, L2-L4 lumbar BMD scores
improved similarly, from 0.57 (z -0.59) to 0.99 (z +0.6).
Figure 1 Sibling A - Fragmentation and destruction of posterior-mid aspect of left talus and right talus, aged 8.
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Left femoral head BMD scores improved from 0.43
(z -3.01) to 0.81 (z -0.7). Only a minor transient self-
resolving fever was observed during the infusion. There
were no other reported side effects.
Post-bisphosphonate therapy, she had one surgical
procedure performed. As a consequence of her left distal
femur fracture, she developed significant leg length dis-
crepancy and severe valgus [Figure 5, 6]. Staples were
inserted into the medial aspect of her left distal femoral
growth plate and bilateral aspects of her right distal
femoral growth plate, with the aim of arrest femoral
growth and correcting her leg length discrepancy.
Case 2
Sibling B was the middle male child of the three sib-
lings. He initially presented in clinic only as part of
Figure 2 Sibling A - Bilateral fragmentation and progressive bony destruction of the distal fibula, with tibial sparing. Disintegration of
both tali. Aged 8 1/2 years.
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follow-up with the other two siblings. Initial x-ray
screening for disease did not find any hip or lower limb
bone disease. He suffered his first bilateral clavicular
fracture at age 7 after falling whilst playing football.
Unusually, he reported feeling some initial pain but con-
tinued to play football after sustaining the fractures.
These fractures were managed conservatively, and
healed slowly with large callous formations at each frac-
ture site. Following this, he had recurrences of clavicular
fractures thereafter.
At age 10 1/2 he presented to the Emergency Depart-
ment complaining of left chest pain. History revealed he
suffered minor trauma to his chest after falling off a
treadmill. Given the family history, a CT chest was per-
formed revealing an osteolytic lesion of the left 6th rib
anteriorly [Figure 7].
Serology revealed normal CRP, FBP, Ca, PO4, Vit D
and ALP. ANA and ESR were not performed. Bone den-
sitometry testing via dual-energy x-ray absorptiometry
was normal for age. Oral Alendronate 40 mg twice
weekly was subsequently commenced, as well as calcium
and vitamin D supplements.
Sibling B experienced an improvement in pain scores
following oral bisphosphonate therapy. Both clavicular
and rib lesions reduced in size clinically. Range of
motion and function assessment was not applicable. At
Figure 3 Sibling A - Clinical photos (posterior and anterior aspects) showing bilateral deformities in both feet and ankles, aged 9.
Figure 4 Sibling A - Reconstituted CT of left distal femur
collapse/impaction, aged 10.
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the time of writing, duration of treatment with bispho-
sphonates is 3 months, hence it is too early to fully ana-
lyse other outcomes and effects from bisphosphonate
therapy. No adverse effects from therapy were reported.
Case 3
Sibling C was the youngest female of the three siblings.
She had been concurrently reviewed at the same times
as both elder siblings. Onset of clinical findings sugges-
tive of IMO occurred at age 3 when she developed swel-
ling of her right foot. X-rays of her right foot revealed
an irregular broad distal tibial epiphysis and metaphysis,
bony sclerosis in the tarsus, and avascular changes of
her cuboid. She remained largely asymptomatic at this
stage with little progression.
At age 8, clinical examination and investigations
showed that her right ankle osteolysis was slowly pro-
gressing [Figure 8]. A six-month course of IV Pamidro-
nate 1 mg/kg monthly was commenced at this stage as
a prophylactic measure aiming to impede further disease
progression. Oral calcium and vitamin D supplements
were also commenced. Bisphosphonate therapy provided
some analgesic benefit to her right foot, but no differ-
ence was found in range of motion of her right ankle.
Whole body BMD improved from 0.81 (z-score -0.1) to
0.92 (z +1.1) after 12 months. L2 to L4 lumbar BMD
improved from 0.72 (z +0.2) to 0.86 (z +1.4). Femoral
head BMD increased from 0.71 to 0.89 (no z scores
reported). During bisphosphonate therapy, she devel-
oped swelling of her left 5th toe, and pain in her left
ankle. X-rays revealed a pathologic fracture and lucency
of the left 5th toe. X-rays of her right ankle did not
reveal any change of her abnormal epiphyseal osteolytic
process of tibial and distal femoral epiphyses. Treatment
consisted of non weight-bearing, followed by partial
weight bearing with a walker for ambulatory assistance.
Serology including FBP, ESR and CRP were normal.
Post bisphosphonate therapy, she had no further radi-
ologic or clinical deterioration, with stabilisation of
existing osteolysis on radiologic imaging.
At age 9, six months after cessation of Pamidronate
therapy, she suffered an atraumatic spiral fracture of her
Figure 5 Sibling A - Clinical photos showing severe valgus of her left knee and shortening of femur, aged 10 1/2.
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Figure 6 Sibling A - Clinical photos (anterior and posterior aspects) showing deformities of both ankles and feet, aged 10 1/2.
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left proximal femoral shaft [Figure 9]. The fracture was
treated with traction. We continue to follow her
progress.
Sibling C experienced mild abdominal pain as an
adverse effect of bisphosphonate therapy, however this
was transient and did not require treatment. There were
no other adverse effects reported. We have successfully
applied for extension of bisphosphonate therapy with IV
Zoledronic acid for both sibling A and sibling C and
await clinical outcomes.
Discussion
IMO is an interesting yet rare familial osteolytic condi-
tion of largely unknown aetiology. The International
Skeletal Dysplasia Society recently revised their nosology
and classification guidelines in which IMO encompasses
many different osteolytic syndromes. These syndromes
have some overlap of clinical features but commonly
share the same pathogenesis of osteolysis, with a pattern
of familial inheritance. Clinical symptoms or signs
usually occur early in childhood (usually 2nd or 3rd year
of life). Findings include multiple bone and joint pain
and bony “dysplasia” with associated decreased range of
movement and function. Diagnosis is usually made with
characteristic osteolytic changes on radiological investi-
gations. Serologic and histologic investigations are
always negative for classical inflammatory or autoim-
mune causes. Further investigations must always be
initially performed to distinguishing IMO from differen-
tial diagnoses, including inflammatory, autoimmune,
endocrine and metabolic causes. As the pathophysiology
is unknown, differential diagnoses of IMO must include
conditions which cause avascular necrosis. Treatment of
IMO with traditional anti-inflammatory or anti-rheu-
matic medications appears to have little effect on pain
or disease progression. Genetic testing have revealed
possible associations with specific genes such as MMP2,
however sibling A was tested and found not to have a
mutation in MMP2. Our IMO patients may be a unique
form genetically, as it is unusual that these siblings
experienced decreased sensation to pain. One sibling
had hip dysplasia, which is not a characteristic of the
other osteolytic syndromes. In this family, mode of
inheritance was thought to be autosomal recessive as no
other generations were affected.
Bisphosphonates are analogues of inorganic pyropho-
sphate with selectivity to bone rather than other tissue.
Their primary mechanism of action is to either inhibit
osteoclastic activity, reduce osteoclastic recruitment, dif-
ferentiation and resorptive activity, or induce apoptosis
[6], thereby favouring bone formation. Evidence in pae-
diatric use suggests potential benefits, which may
include reduction in pain, increased function and range
of motion, improved BMD, reduced risk of fractures,
and retardation of the natural disease history.
In this case report, we have found that bisphosphonates
in these children with IMO have been beneficial in
improving acute pain and BMD. There was no effect on
range of motion. In two siblings, there was radiologic evi-
dence suggesting that bisphosphonates may retard the
Figure 7 Sibling B - CT Chest showing osteolysis of the left 6th rib, aged 10 1/2.
Lee et al. Pediatric Rheumatology 2010, 8:12
http://www.ped-rheum.com/content/8/1/12
Page 8 of 11
natural history or progression of the disease. We could not
comment on the effects on fracture risk as one sibling
developed a significant fracture post-bisphosphonate, even
following an improvement in BMD. Similarly, we could
not comment on whether bisphosphonates reduce the risk
for further surgical intervention as one sibling required
stapling to correct leg length discrepancy. Bisphosphonate
therapy in these three siblings seemed safe, as reported
side effects were mild and clinically insignificant. Given
that the treatment options for conditions such as IMO are
limited, we conclude that bisphosphonate therapy could
be considered for treatment of IMO as it appears safe and
has potential benefits as described above.
Conclusion
IMO is a rare familial condition which must be consid-
ered in children and adolescents with idiopathic osteo-
lysis of bones affecting other members of the family. The
pathophysiology is thought to be of genetic aetiology but
not well understood. Reported genetic links include
mutations of the MMP2 gene. IMO often mimics the
symptoms of other chronic rheumatologic disorder, and
Figure 8 Sibling C - X-ray of right ankle showing abnormal osteolytic process of epiphyses of distal tibia and fibula, aged 8 yo.
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is often initially misdiagnosed. It is a diagnosis of exclu-
sion, hence investigations must be performed to rule out
other diagnoses. Patients with IMO may benefit from
bisphosphonate therapy. These benefits may include pain
relief, decreased analgesic requirements, improved BMD,
and potentially reducing new fracture or osteolytic col-
lapse risk. Given small numbers seen in any single ter-
tiary centre, further multi-centre studies into safety and
efficacy of bisphosphonate therapy in conditions such as
IMO are warranted.
Consent
Written informed consent was obtained from the patient
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